Mercazole

Thiamazole

Method of action: Antithyroid, Endocrine Therapy, Thyroid Therapy

Treatment option: Hyperthyroidism, Goiter, Thyroidectomy, Thyrotoxicosis, Surgery

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mercazole

Quick Facts

Property	Description
Active Ingredient	Thiamazole (also known as Methimazole)
Form	Tablet
Pharmacological Class	Antithyroid Agent (Thionamide)
General Purpose	To manage the overproduction of thyroid hormones
Origin	Synthetic (Thioimidazole derivative)

Mercazole: Definition, Type, and Active Composition

Mercazole is a potent, prescription-only, synthetic drug whose primary active ingredient is Thiamazole (the International Non-proprietary Name), also known by its United States Adopted Name, Methimazole. It is delivered as a single-ingredient product in a tablet form intended for oral administration. This preparation defines the medicine's core identity: a solid compound consisting solely of the thyroid-suppressing compound, Thiamazole, combined with an oral solid base of excipients. The compound's status as a thioimidazole derivative is clinically recognized for its high efficacy in managing thyroid hyperactivity.

Pharmacological Class and General Therapeutic Goal

Mercazole is officially classified as an Antithyroid Agent belonging to the Thionamide class, which functions as a thyroid hormone synthesis inhibitor. This mechanism is essential for controlling conditions characterized by an overactive thyroid. Its general therapeutic goal is to address the chronic state of hyperthyroidism by reducing the excessive production of the main thyroid hormones, Thyroxine (T4) and Triiodothyronine (T3). This inhibitory action helps the body regain hormonal equilibrium, which is necessary when preparing a patient for thyroid surgery or managing Graves' disease.

Key Relationship: Thiamazole and Carbimazole

The compound Thiamazole maintains a crucial relationship with its chemical relative, Carbimazole, which is chemically defined as an inactive prodrug. This relationship signifies that upon ingestion, the body rapidly and completely converts Carbimazole into Thiamazole, which is the active metabolite responsible for the therapeutic effect. Therefore, regardless of which initial compound is taken (Mercazole, Neo-Mercazole, or Tapazole), the therapeutic action—the reliable suppression of excessive thyroid hormone output—remains identical.

Regulatory References

NIH StatPearls Methimazole

What side effects are possible with Mercazole?

Possible Side Effects and Safety Information

The safety profile of Mercazole (Thiamazole/Methimazole) is defined by officially documented adverse reactions categorized into major, systemic events and more common minor reactions, based on regulatory labeling. The major safety concerns involve rare but serious effects on the Blood and Lymphatic System and Hepatobiliary Disorders.

Serious Systemic Reactions

The most serious documented adverse reactions include Agranulocytosis (a severe drop in white blood cells), which typically occurs in less than 0.5% of patients, and Hepatotoxicity, including rare cases of acute liver failure. Other serious, though rare, reported events are Aplastic Anemia, Vasculitis (often ANCA-positive), and Acute Pancreatitis. Regulatory documents note that agranulocytosis most commonly manifests during the first three months of treatment.

Adverse Reaction Category	Examples of Officially Documented Effects
Skin and Subcutaneous	Skin rash, Urticaria, Pruritus, Hair loss
Gastrointestinal	Nausea, Vomiting, Epigastric distress
Musculoskeletal	Arthralgia (Joint pain), Myalgia (Muscle pain)

Population-Specific Constraints

Mercazole is associated with a risk of Fetal Harm when administered in the first trimester of pregnancy, including the potential for congenital malformations such as aplasia cutis. It is contraindicated in patients with a history of acute pancreatitis following previous exposure to Thiamazole or its prodrug, Carbimazole. Caution is required when treating Older Adults and those with Hepatic Impairment due to reduced drug clearance or increased baseline risks.

Overdose and Emergency Response

The official regulatory documents for Mercazole (Thiamazole/Methimazole) define a specific overdose profile centered on both immediate and severe delayed clinical manifestations. Acute signs following an overdose may include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema.

However, the most severe outcomes are documented to be delayed, potentially manifesting hours to days later, and involve life-threatening hematologic toxicity. These severe events include agranulocytosis and aplastic anemia (pancytopenia), as well as less frequent instances of hepatitis, nephrotic syndrome, and neuropathies.

Due to the risk of severe, delayed effects, regulators mandate that immediate medical attention must be sought for any suspected overdose. The official prescribing information directs users to contact a certified Regional Poison Control Center for guidance.

Management is officially described as providing appropriate symptomatic and supportive treatment. No specific antidote is known or documented. Furthermore, interventions such as forced diuresis, hemodialysis, or charcoal hemoperfusion are noted as not established as beneficial for management. Close medical monitoring is required to track for signs of adverse reactions, particularly related to bone marrow function.

Therapeutic Uses of Mercazole

Mercazole: Main Therapeutic Uses and Benefits

Mercazole (Thiamazole/Methimazole) is a key component of medical treatment for hyperthyroidism—the condition characterized by excessive production of thyroid hormones. It is centrally relevant in managing its most common underlying causes, including Graves' disease and toxic multinodular goiter. The primary therapeutic goal is the control of this hormonal excess, which supports efforts to achieve and maintain a stable, normal thyroid function (euthyroid state), which assists with long-term management of the condition.

The medication plays a role in managing symptom clusters that may become intense or disruptive and interfere with daily functioning. It provides supportive relief by easing manifestations of systemic hyperactivity such as a persistent rapid heartbeat and nervousness, and is commonly used to help with signs of metabolic excess, including unexplained weight loss and extreme heat intolerance. It assists with maintaining functional stability and supports the patient by reducing the overall symptom burden.

Mercazole is applied in clinical settings that involve acute or unstable symptom patterns. It is frequently used to ensure the patient is safely brought to a euthyroid state prior to thyroidectomy or before and after radioactive iodine therapy, which helps manage potential acute issues during procedures. Furthermore, it may be part of symptomatic management for both adults and pediatric patients in situations where long-term medical therapy is required.

Quick Fact: Supportive Management of Heightened Symptoms

Symptom Domain	Key Benefit Provided
Cardiovascular Strain	Supports the management of persistent rapid heartbeat and tremor.
Metabolic Distress	Assists with managing chronic issues like unexplained weight loss and heat intolerance.
Clinical Scenarios	Relevant for symptom management before definitive procedures (like surgery).

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

This information details the officially documented eligibility and non-eligibility criteria for Mercazole (carbimazole).

Populations Strictly Excluded (Contraindicated)

Mercazole must not be used by patients who have:

A known allergy or severe hypersensitivity to carbimazole, its active metabolite thiamazole, or any other components of the medicine.
A history of acute pancreatitis following prior treatment with carbimazole or thiamazole.
Serious pre-existing hematological disorders, particularly granulocytopenia.
Severe hepatic insufficiency or liver failure.
A retrosternal goitre or existing signs of tracheal compression.

Restricted or Non-Recommended Use

The medicine is generally intended for adults and children over two years of age. Use is not recommended in children under two years due to insufficient safety data.

Population/Condition	Eligibility Status (Official)
Pregnancy	Use is subject to a careful individual risk/benefit assessment, at the lowest effective dose, due to risk of congenital malformations.
Childbearing Potential	Effective contraception must be used during treatment.
Lactation/Breastfeeding	Contraindicated / Not Recommended.
Mild-Moderate Hepatic Impairment	Use with caution; requires close monitoring and may necessitate cessation of treatment.
Inability to Monitor	Not recommended for patients who cannot be regularly monitored (e.g., for blood counts) or who cannot comply with instructions.

What should I know about interactions with other medicines?

The official regulatory documents detail several interaction patterns for Mercazole (Thiamazole/Methimazole) based on changes in the patient's physiological state and specific pharmacodynamic properties. A primary interaction pattern involves the altered clearance of certain co-administered medicines as the patient transitions from a hyperthyroid to a stable euthyroid state. This change in thyroid status may necessitate dosage reductions for drugs such as Theophylline, Digitalis Glycosides, and beta-adrenergic blocking agents, due to the decrease in their clearance rates.

Another key interaction is with Oral Anticoagulants (e.g., Warfarin). Mercazole is noted for its potential to inhibit Vitamin K activity, which can intensify the effect of these anticoagulants. This interaction requires additional monitoring of the patient's coagulation status.

Furthermore, caution is officially documented when Mercazole is co-administered with drugs known to cause myelosuppression or hepatotoxicity, due to the potential for additive risk of these adverse outcomes. Mercazole absorption is not affected by food intake. Use of the medicine is restricted for nursing mothers and is considered contraindicated in patients with a history of acute pancreatitis following exposure to the drug.

Mechanism of Action

The core mechanism of Mercazole relies on its active molecule, Thiamazole, to act as a direct inhibitor of the enzyme Thyroid Peroxidase ( TPO). This enzyme is essential for thyroid hormone biosynthesis within the follicular cells. Thiamazole binds to the TPO enzyme as a competitive substrate, preventing it from catalyzing two critical reactions: the iodination of tyrosine residues and the subsequent coupling of these iodotyrosines. This molecular blockade immediately halts the synthesis of new Thyroxine ( T4) and Triiodothyronine ( T3) molecules, initiating the process of reducing the rate of thyroid hormone release into the circulation. This synthesis blockade is subject to a physiological constraint: it does not affect the large supply of pre-formed T4 and T3 already stored in the thyroid. The full systemic effect of the synthesis inhibition emerges only as this stored hormone pool is utilized and depleted by the body. The related pro-drug, Carbimazole, is rapidly converted to Thiamazole, resulting in a consistent physiological mechanism focused on synthesis suppression.

Dosage and Administration Information

How to use Mercazole

The usage of Mercazole (Thiamazole/Methimazole) is governed by official prescribing information that details a multi-phased approach to administration and dose adjustment, structured around the patient's clinical response. The medicine is supplied as an oral tablet for ingestion by mouth.

Official Administration Guidelines

Instruction Entity	Regulatory Guideline
Route of Administration	The medicine is administered orally (by mouth).
Dosing Schedule (Initial)	Initial daily dosing is stratified by severity: 15 mg for mild, 30 mg to 40 mg for moderately severe, and 60 mg for severe conditions.
Maintenance Dosing	Once the euthyroid state is achieved, the daily dose is typically reduced to 5 mg to 15 mg.
Frequency Pattern	The initial total daily dosage is usually given in three equally divided doses at approximately 8-hour intervals. The maintenance dose may often be consolidated into a single daily intake.
Age-Group Rules	Pediatric patients are started on a daily dose of 0.4 mg/kg of body weight, divided into three doses, with the maintenance dose being approximately one-half of the initial dose.
Missed Dose Rule	If a dose is missed, it should be taken as soon as possible. If it is almost time for the next dose, the missed dose should be skipped to avoid doubling the next scheduled amount.

Official Procedural Structure

The treatment protocol begins with the administration of the total daily dose in multiple, divided portions to ensure consistent presence of the drug during the initial phase. After clinical normalization, typically within 4 to 12 weeks, the daily dosage is substantially reduced for the maintenance phase. Therapy may be administered for a prolonged course, often 12 to 18 months, or used as a short-term preparatory measure before procedures such as thyroidectomy or radioactive iodine therapy.

Recent Clinical Evidence

Mercazole: Recent Clinical Evidence

This overview summarizes the structure of clinical research, including trials and observational studies, that have examined Mercazole (Thiamazole/Methimazole) for managing hyperthyroidism. Findings describe group patterns observed in studies and contribute to the broader evidence landscape. Research does not determine whether an individual will respond similarly.

Evidence for Managing Graves' Disease

Research on Graves' disease was evaluated in numerous Randomized Controlled Trials (RCTs) and subsequently analyzed in Meta-analyses. These studies monitored specific outcomes, including the normalization of thyroid hormone biomarkers (free T4 and T3) and the rate of disease remission (stable thyroid function after the medicine is stopped). Study populations included both adults and pediatric patients. Studies monitored the biochemical normalization of thyroid hormone levels, and data show patterns related to hyperthyroidism relapse following treatment completion.

Evidence for Sustained Control in Chronic Hyperthyroidism

For conditions characterized by chronic hyperthyroidism, such as toxic multinodular goiter, Mercazole was studied in Long-term Observational Studies and Randomized Clinical Trials. These studies evaluated the sustained duration of the euthyroid state over many years of therapy, with researchers monitoring cardiovascular outcomes in the context of long-term thyroid function stability. Studies reported patterns related to thyroid function control in cohorts observed over long periods.

Research on Pre-Procedural Stabilization

Mercazole was evaluated in research scenarios involving heightened symptom activity and prior to medical procedures. These short-term studies monitored the time required to achieve the normalization of free thyroid hormone levels. Trials reported the biochemical shift in thyroid hormone levels following the initiation of treatment, with findings focused on short-term biochemical stabilization.

Key Limitations and Areas of Research Uncertainty

The quality of evidence varies across studies. Sample sizes were modest in some specific trials, and follow-up durations were limited when assessing the very long-term effects. The question of the optimal duration of therapy remains an area where data are still emerging, and research is ongoing. Data for certain subgroups, such as patients with specific co-morbidities, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Mercazole (FAQ)

Q: What is Mercazole used for?

Mercazole (methimazole) is an antithyroid medication used to treat hyperthyroidism (an overactive thyroid gland).

It is often used before thyroid surgery or radioactive iodine treatment. It may also be used in patients who cannot have surgery or radioactive iodine treatment.

Q: How does Mercazole work?

Mercazole works by preventing the thyroid gland from making too much thyroid hormone. It does this by blocking an enzyme that helps combine iodine with a protein called thyroglobulin, a critical step in producing T3 and T4 hormones.

Q: How should I take Mercazole?

Mercazole is taken by mouth, usually once or twice a day, as directed by your doctor. It can be taken with or without food, but taking it the same way each day helps maintain consistent levels in your body.

Do not stop taking Mercazole without talking to your healthcare provider, even if you start to feel better.
If you miss a dose, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and return to your regular dosing schedule. Do not double doses.

Q: What are the common side effects of Mercazole?

Common side effects of Mercazole may include:

Nausea or stomach upset
Headache
Joint and muscle pain
Skin rash or itching
Hair loss

These side effects are usually mild and may lessen as your body adjusts to the medication. Consult your doctor if these symptoms persist or worsen.

Q: What are the serious side effects I should watch for?

Though rare, Mercazole can cause serious side effects. Contact your doctor immediately if you experience any of the following:

Signs of liver problems, such as dark urine, yellowing of the skin or eyes (jaundice), severe stomach pain, or persistent nausea.
Signs of agranulocytosis (a severe drop in white blood cells), such as fever, chills, sore throat, or other signs of infection. This is a rare but serious side effect.
Signs of vasculitis, such as a severe rash, kidney problems, or joint pain.

Regular blood tests are necessary while taking this medication to monitor your thyroid function and blood counts.

How should Mercazole be stored and disposed of?

Storage and Disposal of Mercazole (Carbimazole)

The official storage conditions for Mercazole tablets mandate specific temperature and environmental protection rules to maintain product stability and safety.

Storage Requirements

Scope Element	Regulatory Requirement
Temperature	Must be stored at or below 25 C.
Packaging	Must be kept in the original container.
Child Safety	Must be stored out of the sight and reach of children.

Tablets must also be protected from heat and dampness and should not be disposed of as general household trash. Unused or expired medication must not be thrown into wastewater. Disposal must be performed in accordance with local requirements, typically by asking a pharmacist for the proper return pathway.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Japan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z